• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

可溶性尿激酶型纤溶酶原激活物受体，一种循环性肾脏疾病因子。

suPAR, a Circulating Kidney Disease Factor.

作者信息

Wei Changli, Spear Ryan, Hahm Eunsil, Reiser Jochen

机构信息

Department of Medicine, Rush University Medical Center, Chicago, IL, United States.

出版信息

Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.

DOI:10.3389/fmed.2021.745838
PMID:34692736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8526732/
Abstract

Urokinase plasminogen activator receptor (uPAR) is a multifaceted, GPI-anchored three-domain protein. Release of the receptor results in variable levels of soluble uPAR (suPAR) in the blood circulation. suPAR levels have been linked to many disease states. In this mini-review, we discuss suPAR as a key circulating molecule mediating kidney disease with a particular focus on differently spliced isoforms.

摘要

尿激酶型纤溶酶原激活物受体（uPAR）是一种多面的、糖基磷脂酰肌醇锚定的三结构域蛋白。该受体的释放导致血液循环中可溶性uPAR（suPAR）水平的变化。suPAR水平与多种疾病状态相关。在这篇小型综述中，我们将讨论suPAR作为介导肾脏疾病的关键循环分子，特别关注不同剪接异构体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c2/8526732/dd38d76e5290/fmed-08-745838-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c2/8526732/d9bd8ac054e5/fmed-08-745838-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c2/8526732/dd38d76e5290/fmed-08-745838-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c2/8526732/d9bd8ac054e5/fmed-08-745838-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29c2/8526732/dd38d76e5290/fmed-08-745838-g0002.jpg

相似文献

1
suPAR, a Circulating Kidney Disease Factor.可溶性尿激酶型纤溶酶原激活物受体，一种循环性肾脏疾病因子。
Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.
2
Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.来自人类免疫缺陷病毒1型感染患者的刺激全血培养物中完整和裂解的尿激酶受体释放减少。
Scand J Immunol. 2005 Apr;61(4):347-56. doi: 10.1111/j.1365-3083.2005.01582.x.
3
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.玻连蛋白通过捕获可溶性尿激酶受体-尿激酶复合物，将蛋白水解活性集中于细胞表面和细胞外基质。
Blood. 1998 Apr 1;91(7):2305-12.
4
Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.可溶性尿激酶型纤溶酶原激活物受体通过对细胞信号传导的直接、不依赖尿激酶的作用来抑制癌细胞生长和侵袭。
J Biol Chem. 2003 Nov 21;278(47):46692-8. doi: 10.1074/jbc.M308808200. Epub 2003 Sep 8.
5
Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).可溶性尿激酶受体（suPAR）与尿激酶氨基末端片段（1-143）复合物的结晶。
Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):697-700. doi: 10.1107/S0907444905014174. Epub 2005 May 26.
6
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.尿激酶催化的尿激酶受体裂解需要完整的糖脂锚。
Biochem J. 2001 Sep 15;358(Pt 3):673-9. doi: 10.1042/0264-6021:3580673.
7
Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.尿激酶型纤溶酶原激活物受体及其可溶性形式在 2 型糖尿病肾病中的表达。
Arch Med Res. 2019 Jul;50(5):249-256. doi: 10.1016/j.arcmed.2019.08.007. Epub 2019 Oct 5.
8
Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.尿激酶型纤溶酶原激活物受体及其可溶性形式在常见活检证实的肾脏疾病和糖尿病肾病分期中的作用
Clin Biochem. 2015 Dec;48(18):1324-9. doi: 10.1016/j.clinbiochem.2015.07.001. Epub 2015 Jul 8.
9
Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.可溶性尿激酶型纤溶酶原激活物受体和尿激酶型纤溶酶原激活物受体促成白血病中的化疗耐药性。
Oncol Lett. 2017 Jul;14(1):383-389. doi: 10.3892/ol.2017.6150. Epub 2017 May 10.
10
Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.可溶性尿激酶型纤溶酶原激活物受体水平反映系统性红斑狼疮中的器官损伤。
Transl Res. 2013 Nov;162(5):287-96. doi: 10.1016/j.trsl.2013.07.003. Epub 2013 Aug 1.

引用本文的文献

1
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.重症 COVID-19 患者的生物标志物与早发性急性肾损伤：一项前瞻性单中心观察性研究
BMC Nephrol. 2025 Jul 1;26(1):294. doi: 10.1186/s12882-025-04267-0.
2
Development of animal models with chronic kidney disease-mineral and bone disorder based on clinical characteristics and pathogenesis.基于临床特征和发病机制的慢性肾脏病-矿物质和骨异常动物模型的建立
Front Endocrinol (Lausanne). 2025 Mar 25;16:1549562. doi: 10.3389/fendo.2025.1549562. eCollection 2025.
3
Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.

本文引用的文献

1
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.11 个基因组位点影响慢性炎症标志物可溶性尿激酶型纤溶酶原激活物受体的血浆水平。
Commun Biol. 2021 Jun 2;4(1):655. doi: 10.1038/s42003-021-02144-8.
2
Single-cell RNA counting at allele and isoform resolution using Smart-seq3.基于 Smart-seq3 技术进行等位基因和异构体分辨率的单细胞 RNA 计数
Nat Biotechnol. 2020 Jun;38(6):708-714. doi: 10.1038/s41587-020-0497-0. Epub 2020 May 4.
3
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
局灶节段性肾小球硬化及相关疾病的发病机制
Annu Rev Pathol. 2025 Jan;20(1):329-353. doi: 10.1146/annurev-pathol-051220-092001.
4
Biomarkers of chronic kidney disease in older individuals: navigating complexity in diagnosis.老年个体慢性肾脏病的生物标志物：应对诊断中的复杂性
Front Med (Lausanne). 2024 Jul 11;11:1397160. doi: 10.3389/fmed.2024.1397160. eCollection 2024.
5
Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.尿激酶型纤溶酶原激活物受体（uPAR）在炎症与疾病中的作用：一种独特的炎症途径激活剂
Biomedicines. 2024 May 24;12(6):1167. doi: 10.3390/biomedicines12061167.
6
suPAR links a dysregulated immune response to tissue inflammation and sepsis-induced acute kidney injury.suPAR 将失调的免疫反应与组织炎症和脓毒症引起的急性肾损伤联系起来。
JCI Insight. 2023 Apr 10;8(7):e165740. doi: 10.1172/jci.insight.165740.
7
Ion channels and channelopathies in glomeruli.离子通道与肾小球中的通道病。
Physiol Rev. 2023 Jan 1;103(1):787-854. doi: 10.1152/physrev.00013.2022. Epub 2022 Aug 25.
8
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体：肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
可溶性尿激酶型纤溶酶原激活物受体（suPAR）在局灶节段性肾小球硬化症中的诊断和预后价值及其检测方法的影响。
Sci Rep. 2019 Sep 24;9(1):13783. doi: 10.1038/s41598-019-50405-8.
4
c-Src is in the effector pathway linking uPAR and podocyte injury.c-Src 位于连接 uPAR 和足细胞损伤的效应子途径中。
J Clin Invest. 2019 Apr 2;129(5):1827-1829. doi: 10.1172/JCI127927.
5
uPAR isoform 2 forms a dimer and induces severe kidney disease in mice.uPAR 同种型 2 形成二聚体并在小鼠中诱导严重肾脏疾病。
J Clin Invest. 2019 Apr 2;129(5):1946-1959. doi: 10.1172/JCI124793.
6
Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.监测接受治疗性血浆置换和利妥昔单抗治疗的肾移植后局灶节段性肾小球硬化症患者的 suPAR 水平。
BMC Nephrol. 2018 Dec 17;19(1):361. doi: 10.1186/s12882-018-1177-x.
7
suPAR and chronic kidney disease-a podocyte story.可溶性尿激酶型纤溶酶原激活物受体与慢性肾脏病——足细胞的故事
Pflugers Arch. 2017 Aug;469(7-8):1017-1020. doi: 10.1007/s00424-017-2026-7. Epub 2017 Jul 8.
8
A tripartite complex of suPAR, APOL1 risk variants and αβ integrin on podocytes mediates chronic kidney disease.足细胞上的suPAR、APOL1风险变异体和αβ整合素三方复合物介导慢性肾脏病。
Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.
9
Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.使用CytoSorb去除局灶节段性肾小球硬化（FSGS）因子可溶性尿激酶型纤溶酶原激活物受体（suPAR）。
J Clin Apher. 2017 Dec;32(6):444-452. doi: 10.1002/jca.21538. Epub 2017 Mar 29.
10
Focal Segmental Glomerulosclerosis.局灶节段性肾小球硬化症
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517. doi: 10.2215/CJN.05960616. Epub 2017 Feb 27.